Replies to post #27624 on Marker Therapeutics Inc (MRKR)

[rfj1862]

So PL and rfj now that you have seen the PR what are your thoughts?

I think the data are incredibly impressive.

I actually was involved in the launch of Abraxane for pancreatic cancer years ago and we were over the moon for a 23% ORR (if I recall correctly) when combined with gemcitabine. This treatment itself virtually killed patients due to numerous and severe toxicities...but it was certainly an advance over gemcitabine monotherapy.

If these data hold up as more patients are enrolled there's no question in my mind that they have a viable product. I would love to see this in NSCLC, or more likely SCLC initially since there are very limited treatment options for the latter. If they tested it in SCLC they could possibly get better PS patients since they have so few options.

I will reiterate that I am disappointed in how management handled this trial. Contemporaneous release of the PR would likely have mitigated the decline.

Also I am done here. Posts are getting deleted, there's no point in wasting time on this.